Advances in Antibody–Drug Conjugates for Treatment of Non-Small-Cell Lung Cancer

Join us for this dynamic, CME-certified webinar in which lung cancer experts will review the evolving role of antibody–drug conjugates in the treatment of non-small-cell lung cancer, including patient case discussions and discussion of new data recently presented at WCLC 2020.

Sign up now!

Please note that this live Webinar will feature the expert faculty, along with interactivity, evidence-based content, and panel discussions. When participating in a live Webinar, you will be able to text questions directly to the faculty and the planned agenda allows time for the faculty to discuss and answer submitted questions.

To Register: On the Event Dates page, click a date/time and click the blue Register button in the upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.

Thank you,
CCO Member Services

Agenda

Welcome, Introduction, and Baseline Assessment

Introduction to Antibody–Drug Conjugates for Treatment of Non-Small-Cell Lung Cancer

  • Overview/introduction to ADCs

Activity of Antibody Drug Conjugates in NSCLC Clinical Trials

  • HER2-altered NSCLC
  • Other ADC targets in NSCLC

Summary, Final Thoughts, Posteducation Assessment, and Audience Question and Answer Session

Events

Date / Time
Event Details

Faculty

Program Director
Ross Camidge, MD, PhD

Professor of Medicine,
Division of Medical Oncology
University of Colorado
USA

Faculty
Joel Neal, MD

Associate Professor of Medicine
Division of Oncology
Department of Medicine
Stanford University
Attending Physician
Stanford Cancer Institute
Palo Alto, California

Goal Statement
The goal of this activity is to improve the knowledge and competence of learners in integrating emerging antibody–drug conjugate therapies into lung cancer treatment paradigms.

Target Audience
This program is intended for global medical oncologists and other healthcare providers who care for patients with lung cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Identify features that affect the efficacy and toxicity of antibody–drug conjugates
  • Assess clinical data for antibody-drug conjugates being studied in advanced NSCLC
  • Explain rationale and assessments of HER2 and other antibody-drug conjugate targets in NSCLC
  • Evaluate emerging strategies for using antibody-drug conjugates to overcome EGFR TKI resistance

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Provided by Clinical Care Options, LLC

Supported by an educational grant from

Daiichi Sankyo, Inc.

There are no fees required to participate in this activity.